Literature DB >> 19771482

Use of aspirin among diabetics in the primary prevention of cardiovascular disease: need for reliable randomized evidence and astute clinical judgment.

Patricia R Hebert1, Wendy R Schneider, Charles H Hennekens.   

Abstract

BACKGROUND: The American Heart Association Guidelines recommend aspirin for all apparently healthy individuals whose 10-year risk of a first coronary heart disease (CHD) event is >10%.
METHODS: The United States (US) Preventive Services Task Force (USPSTF) has recently updated its guidelines to encourage men 45 to 79 years and women 55 to 79 years to use aspirin when the potential benefit outweighs the potential harm. In addition, in some US guidelines, diabetes is considered to be a CHD risk equivalent.
RESULTS: Two recently published trials, the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) and the Prevention of Progression of Arterial Disease and Diabetes (POPADAD), concluded that aspirin did not reduce risks of CHD. Both JPAD and POPADAD had inadequate statistical power. Reliable randomized evidence is necessary to provide a sufficient totality of evidence about benefits and risks among diabetics.
CONCLUSION: At present, astute individual clinical judgments are necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19771482      PMCID: PMC2771233          DOI: 10.1007/s11606-009-1095-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Aspirin therapy in diabetes.

Authors:  John A Colwell
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 3.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

4.  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis.

Authors:  Charles H Hennekens; Danielle Hollar; Colin Baigent
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2006-01

5.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

6.  Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians.

Authors:  J E Manson; D E Grobbee; M J Stampfer; J O Taylor; S Z Goldhaber; J M Gaziano; P M Ridker; J E Buring; C H Hennekens
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

7.  Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey.

Authors:  D B Rolka; A Fagot-Campagna; K M Narayan
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

8.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2009-03-17       Impact factor: 25.391

9.  Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators.

Authors: 
Journal:  JAMA       Date:  1992-09-09       Impact factor: 56.272

10.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

Authors:  Jill Belch; Angus MacCuish; Iain Campbell; Stuart Cobbe; Roy Taylor; Robin Prescott; Robert Lee; Jean Bancroft; Shirley MacEwan; James Shepherd; Peter Macfarlane; Andrew Morris; Roland Jung; Christopher Kelly; Alan Connacher; Norman Peden; Andrew Jamieson; David Matthews; Graeme Leese; John McKnight; Iain O'Brien; Colin Semple; John Petrie; Derek Gordon; Stuart Pringle; Ron MacWalter
Journal:  BMJ       Date:  2008-10-16
View more
  2 in total

Review 1.  Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.

Authors:  David R Saxon; Neda Rasouli; Robert H Eckel
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 2.  Platelets, diabetes and myocardial ischemia/reperfusion injury.

Authors:  Isabella Russo; Claudia Penna; Tiziana Musso; Jasmin Popara; Giuseppe Alloatti; Franco Cavalot; Pasquale Pagliaro
Journal:  Cardiovasc Diabetol       Date:  2017-05-31       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.